Pharsight

Atelvia patents expiration

ATELVIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5583122 APIL Pharmaceutical compositions containing geminal diphosphonates
Dec, 2013

(10 years ago)

US5622721 APIL Dosage forms of risedronate
Apr, 2014

(10 years ago)

US5583122

(Pediatric)

APIL Pharmaceutical compositions containing geminal diphosphonates
Jun, 2014

(10 years ago)

US8246989 APIL Dosage forms of bisphosphonates
Jan, 2026

(1 year, 7 months from now)

US7645460 APIL Dosage forms of risedronate
Jan, 2028

(3 years from now)

US7645459 APIL Dosage forms of bisphosphonates
Jan, 2028

(3 years from now)

Atelvia is owned by Apil.

Atelvia contains Risedronate Sodium.

Atelvia has a total of 6 drug patents out of which 3 drug patents have expired.

Expired drug patents of Atelvia are:

  • US5583122
  • US5622721
  • US5583122*PED

Atelvia was authorised for market use on 08 October, 2010.

Atelvia is available in tablet, delayed release;oral dosage forms.

Atelvia can be used as treatment of osteoporosis in postmenopausal women.

The generics of Atelvia are possible to be released after 09 January, 2028.

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Oct 08, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RISEDRONATE SODIUM ingredient

Market Authorisation Date: 08 October, 2010

Treatment: Treatment of osteoporosis in postmenopausal women

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of ATELVIA before it's drug patent expiration?
More Information on Dosage

ATELVIA family patents

Family Patents